157 related articles for article (PubMed ID: 31900526)
1. Lessons learned from using fMRI in the early clinical development of a mu-opioid receptor antagonist for disorders of compulsive consumption.
Nathan PJ; Bakker G
Psychopharmacology (Berl); 2021 May; 238(5):1255-1263. PubMed ID: 31900526
[TBL] [Abstract][Full Text] [Related]
2. Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people.
Cambridge VC; Ziauddeen H; Nathan PJ; Subramaniam N; Dodds C; Chamberlain SR; Koch A; Maltby K; Skeggs AL; Napolitano A; Farooqi IS; Bullmore ET; Fletcher PC
Biol Psychiatry; 2013 May; 73(9):887-94. PubMed ID: 23245760
[TBL] [Abstract][Full Text] [Related]
3. The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours.
Kelly E; Mundell SJ; Sava A; Roth AL; Felici A; Maltby K; Nathan PJ; Bullmore ET; Henderson G
Psychopharmacology (Berl); 2015 Jan; 232(1):305-14. PubMed ID: 24973897
[TBL] [Abstract][Full Text] [Related]
4. Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.
Chamberlain SR; Mogg K; Bradley BP; Koch A; Dodds CM; Tao WX; Maltby K; Sarai B; Napolitano A; Richards DB; Bullmore ET; Nathan PJ
Psychopharmacology (Berl); 2012 Dec; 224(4):501-9. PubMed ID: 22752384
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating.
Giuliano C; Robbins TW; Nathan PJ; Bullmore ET; Everitt BJ
Neuropsychopharmacology; 2012 Nov; 37(12):2643-52. PubMed ID: 22805601
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans.
Rabiner EA; Beaver J; Makwana A; Searle G; Long C; Nathan PJ; Newbould RD; Howard J; Miller SR; Bush MA; Hill S; Reiley R; Passchier J; Gunn RN; Matthews PM; Bullmore ET
Mol Psychiatry; 2011 Aug; 16(8):826-35, 785. PubMed ID: 21502953
[TBL] [Abstract][Full Text] [Related]
7. Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects.
Ziauddeen H; Chamberlain SR; Nathan PJ; Koch A; Maltby K; Bush M; Tao WX; Napolitano A; Skeggs AL; Brooke AC; Cheke L; Clayton NS; Sadaf Farooqi I; O'Rahilly S; Waterworth D; Song K; Hosking L; Richards DB; Fletcher PC; Bullmore ET
Mol Psychiatry; 2013 Dec; 18(12):1287-93. PubMed ID: 23147384
[TBL] [Abstract][Full Text] [Related]
8. The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.
Ripley TL; Sanchez-Roige S; Bullmore ET; Mugnaini M; Maltby K; Miller SR; Wille DR; Nathan P; Stephens DN
Psychopharmacology (Berl); 2015 Sep; 232(18):3431-41. PubMed ID: 26141191
[TBL] [Abstract][Full Text] [Related]
9. Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist.
Ignar DM; Goetz AS; Noble KN; Carballo LH; Stroup AE; Fisher JC; Boucheron JA; Brainard TA; Larkin AL; Epperly AH; Shearer TW; Sorensen SD; Speake JD; Hommel JD
J Pharmacol Exp Ther; 2011 Oct; 339(1):24-34. PubMed ID: 21712426
[TBL] [Abstract][Full Text] [Related]
10. Response to paper by Kelly et al "The opioid receptor pharmacology of GSK1521498 compared to other ligands with different effects on compulsive reward-related behaviors" published in Psychopharmacology 232, 305-314, 2014.
Wang D; Sadee W
Psychopharmacology (Berl); 2015 Apr; 232(8):1493-4. PubMed ID: 25740344
[No Abstract] [Full Text] [Related]
11. Dopamine and μ-opioid receptor dysregulation in the brains of binge-eating female rats - possible relevance in the psychopathology and treatment of binge-eating disorder.
Heal DJ; Hallam M; Prow M; Gosden J; Cheetham S; Choi YK; Tarazi F; Hutson P
J Psychopharmacol; 2017 Jun; 31(6):770-783. PubMed ID: 28376679
[TBL] [Abstract][Full Text] [Related]
12. Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist.
Nathan PJ; O'Neill BV; Bush MA; Koch A; Tao WX; Maltby K; Napolitano A; Brooke AC; Skeggs AL; Herman CS; Larkin AL; Ignar DM; Richards DB; Williams PM; Bullmore ET
J Clin Pharmacol; 2012 Apr; 52(4):464-74. PubMed ID: 21610207
[TBL] [Abstract][Full Text] [Related]
13. Reply to Wang and Sadée.
Henderson G; Bullmore ET
Psychopharmacology (Berl); 2015 Apr; 232(8):1495-6. PubMed ID: 25757674
[No Abstract] [Full Text] [Related]
14. The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects.
Ziauddeen H; Nathan PJ; Dodds C; Maltby K; Miller SR; Waterworth D; Song K; Warren L; Hosking L; Zucchetto M; Bush M; Johnson LV; Sarai B; Mogg K; Bradley BP; Richards DB; Fletcher PC; Bullmore ET
J Clin Pharmacol; 2013 Oct; 53(10):1078-90. PubMed ID: 23934621
[TBL] [Abstract][Full Text] [Related]
15. Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery.
Nathan PJ; Phan KL; Harmer CJ; Mehta MA; Bullmore ET
Curr Opin Pharmacol; 2014 Feb; 14():54-61. PubMed ID: 24565013
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a Long-Lasting Compulsive Alcohol Seeking Phenotype in Rats.
Giuliano C; Peña-Oliver Y; Goodlett CR; Cardinal RN; Robbins TW; Bullmore ET; Belin D; Everitt BJ
Neuropsychopharmacology; 2018 Mar; 43(4):728-738. PubMed ID: 28553834
[TBL] [Abstract][Full Text] [Related]
17. Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498.
Nathan PJ; Bush MA; Tao WX; Koch A; Davies KM; Maltby K; O'Neill BV; Napolitano A; Skeggs AL; Brooke AC; Richards DB; Williams PM; Bullmore ET
J Clin Pharmacol; 2012 Oct; 52(10):1456-67. PubMed ID: 22162534
[TBL] [Abstract][Full Text] [Related]
18. The mu-opioid receptor subtype is required for the anorectic effect of an opioid receptor antagonist.
Zhang J; Frassetto A; Huang RR; Lao JZ; Pasternak A; Wang SP; Metzger JM; Strack AM; Fong TM; Chen RZ
Eur J Pharmacol; 2006 Sep; 545(2-3):147-52. PubMed ID: 16876155
[TBL] [Abstract][Full Text] [Related]
19. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
[TBL] [Abstract][Full Text] [Related]
20. Mu-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy.
Sirohi S; Kumar P; Yoburn BC
J Pharmacol Exp Ther; 2007 Nov; 323(2):701-7. PubMed ID: 17698975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
